[{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tildrakizumab","moa":"IL-23","graph1":"Dermatology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Remdesivir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation powder","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Nicox SA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Cetirizine","moa":"H1 receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"ophthalmic solution","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"AFT Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NEW ZEALAND","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"COX-1","graph1":"Neurology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceutical"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Meropenem","moa":"D-alanyl-D-alanine carboxypeptidase DacB","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceutical"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation powder","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu Opoid receptor","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hydralazine Hydrochloride","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Estradiol Valerate","moa":"Estrogen receptor alpha","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Hikma Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.14999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Faes Farma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceutical"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Hikma Pharmaceuticals \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"HUNGARY","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"RANK","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Hikma","highestDevelopmentStatusID":"10","companyTruncated":"Hikma Pharmaceuticals \/ Hikma"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1","graph1":"Immunology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Teligent, Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Atropine","moa":"mAChRs","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Hikma Pharmaceuticals \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Custopharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0.42999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.42999999999999999,"dosageForm":"Injection","sponsorNew":"Hikma Pharmaceuticals \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Custopharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0.42999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.42999999999999999,"dosageForm":"Injection","sponsorNew":"Hikma Pharmaceuticals \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.10000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Vectura Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Hikma Pharmaceuticals \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Vectura Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Hikma Pharmaceuticals \/ Hikma","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Olopatadine Hydrochloride","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Toripalimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Dobutamine Hydrochloride","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Rakuten Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Cetuximab Sarotalocan Sodium","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"CanariaBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Oregovomab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hikma Pharmaceuticals \/ CanariaBio","highestDevelopmentStatusID":"10","companyTruncated":"Hikma Pharmaceuticals \/ CanariaBio"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tapentadol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hikma Pharmaceuticals \/ Emergent BioSolutions","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Emergent BioSolutions"}]
Find Clinical Drug Pipeline Developments & Deals by Hikma Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
